Skip to main content
Fig. 1 | BMC Ophthalmology

Fig. 1

From: Efficacy and safety of 0.05% micellar nano-particulate (MNP) cyclosporine ophthalmic emulsion in the treatment of moderate-to-severe keratoconjunctivitis sicca: a 12-week, multicenter, randomized, active-controlled trial

Fig. 1

Difference in mean scores versus control with 95% confidence intervals†

† PP population at 12 weeks. 1 = CFSS; 2 = STT; 3 = CLGS; 4 = OSDI; 5 = Blurring; 6 = Dry eyes; 7 = Itching; 8 = Photophobia; 9 = Painful/sore eyes; 10 = Sandy/gritty eyes; 11 = Stinging/burning.

Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us